Raja Velagapudi

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Michael H. Weisman, Larry W. Moreland, Daniel E. Furst et al. · Clinical Therapeutics · 2003 · 299 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

Alfons A den Broeder, Leo van de Putte, Rolf Rau et al. · PubMed · 2002 · 195 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

James J. Gallagher, Charles J. Fisher, Bruce W. Sherman et al. · Intensive Care Medicine · 2001 · 59 citations

Veterinary Medicine, Immunology, Pharmacokinetics +16

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Miguel A. Villalona‐Calero, Joseph P. Eder, Deborah Toppmeyer et al. · Journal of Clinical Oncology · 2001 · 37 citations

Medicine, Oncology, Pharmacology +16

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

Miguel A. Villalona‐Calero, Sharyn D. Baker, L. A. Hammond et al. · Journal of Clinical Oncology · 1998 · 32 citations

Medicine, Oncology, Pharmacology +12